| Technical Name | R&D of the first-in-class anti-diabetic drug, PS1 | ||
|---|---|---|---|
| Project Operator | academia sinica | ||
| Project Host | 楊文欽 | ||
| Summary | This invention is to apply PS1 to treatreverse T2D. The invention can be developed into small-molecule drugs. Those are first-in-class drugs for T2D because its novel anti-diabetic mode of action. | ||
| Technical Film |
|
||
| Market Potential Analysis | 糖尿病目前無法逆轉或治癒。全球糖尿病患者超過4.6億(台灣約160萬人罹患糖尿病) ，每年全球藥物市場達500億美元。本發明所發展新藥可以逆轉糖尿病，申請PX和PS1(PX抑制劑)的專利(部分專利已獲得)。本專利之經濟效益可佔250億美元。 | ||
| Industrial Applicability | This invention can be applied to development of first-in-class drugshelp pharmaceutical company upgrade their research capacity. | ||
| Keyword | Diabetes Cure reversal PS1 small-molecule drugs first-in-class drugs islet cells cell death Oral agent blood sugar | ||
| Notes | |||
| Download |
20.生技醫藥-新藥_楊文欽.pdf 2020第三梯次團隊手冊文案FV - 複製.pdf |
||
Other people also saw
